Introduction
Endometrial cancer is the most common malignancy of the female genital system in developed countries. In Taiwan, endometrial cancer ranks second among gynecological cancers in its incidence. Risk factors for endometrial cancer are both environmental and genetic. One major environmental risk factor is endogenous or exogenous estrogen exposure: many sources of exogenous estrogen exist, including oral contraceptives and hormone replacement therapy (1) . Some genetic variants involved in the steroid hormone biosynthesis and metabolism pathways may contribute to hyperestrogenic status, which is associated with endometrial cancer risk (2, 3) . Use of oral contraceptives provides significant long-term protection against endometrial cancer (4) . Long-term sequential estrogen-plus-progestin therapy during menopause increases the risk of endometrial cancer, whereas short-term estrogen-plus-progestin use in menopause decreases the risk of endometrial cancer (5) . Endometrial cancer patients who received extended adjuvant tamoxifen do not appear to be at greater risk for endometrial cancer (6) .
Next-generation sequencing (NGS) will play an important role in anticancer drug development (7) and targeted therapy (8) . At present, there are multiple NGS instruments in use, such as the Illumina HiSeq and MiSeq (Illumina, Inc., San Diego, CA, USA), the Ion Torrent Proton and Personal Genome Machine (Life Technologies, Carlsbad, CA, USA), as well as the Roche 454 Sequencer and GS Junior (Roche Applied Biosystems, Nutley, NJ, USA). The Cancer Genome Atlas (TCGA) project used NGS techniques to identify hundreds of somatically altered genes (9) (10) (11) (12) . This technical advance is rapidly altering the routine practice of molecular pathology, from single-gene tests (i.e., Sanger sequencing to assess KRAS mutations in colorectal cancer) to multiplexed NGS assays. Several NGS approaches have been commonly implemented clinically in oncology, including hybrid capture-based panels, multiplexed polymerase chain reaction (PCR)-based panels and comprehensive genome/ transcriptome/exome sequencing (13) (14) (15) (16) . Whole genome sequencing offers high throughput, high accuracy (<1 error per 100 kb) and affordable cost (<$5,000 USD in reagents) (17) . Recently, the American College of Medical Genetics and
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Genomics (ACMG) recommended reporting pathogenic findings in 56 genes with low coverage. Low sequencing coverage may contribute to false negative clinical exome results (18) . Based on histological subtype, endometrial cancer is classified into two major types (I and II). Type I (endometrioid) carcinoma is the most frequent type of endometrial cancer, accounting for over 80% of cases. Type II (non-endometrioid) carcinoma comprises a minority of endometrial cancer cases. Whole-exome sequencing (WES) has led to the discovery of ARID1A as a novel regulator of PI3K pathway activity in endometrioid endometrial cancer (19) . Through an integrated genomic, transcriptomic and proteomic analysis of endometrial cancer, TCGA research has suggested a novel molecular classification for two histological subtypes (12) .
We performed WES on 14 patients with endometrial cancers. Our results identify cancer driver and passenger genes, and adhere to ACMG recommendations for the examination and reporting of secondary genetic findings during clinical genomic testing.
Materials and methods

Patients and samples.
Fourteen patients with endometrial cancer were recruited for this study. DNA was extracted using the QIAamp DNA Micro kit (Qiagen, Heidelberg, Germany) following the manufacturer's protocol. Extracted DNA samples were quantified using NanoDrop 2000 spectrophotometer (Thermal Fisher Scientific, Waltham, MA, USA) and a Qubit fluorometer (Invitrogen, Carlsbad, CA, USA). This study was approved by the Institutional Review Board of Kaohsiung Medical University Hospital (KMUH-IRB-970488).
Whole-exome sequencing. To generate standard exome capture libraries, we used the Agilent SureSelect XT Reagent kit protocol for the Illumina Hiseq paired-end sequencing library (cat. no. G9611A). In all cases, the SureSelect XT Human All Exon Version 4 (51 Mb) probe set was used. We used 50 ng genomic DNA for library construction with the Agilent SureSelect XT Reagent kit. The adapter-ligated sample was purified using Agencourt AMPure XP beads (Beckman Coulter, Brea, CA, USA) and analyzed on a Bioanalyzer DNA 1000 chip. Part of the sample (750 ng) was prepared for hybridization with the capture baits, and the sample was hybridized for 90 min at 65˚C, captured with the Dynabeads MyOne Streptavidin T1 (Life Technologies) and purified using Agencourt AMPure XP beads. The Agilent protocol was used to add index tags by post-hybridization amplification. Finally, all samples were sequenced on an Illumina Hiseq system using 100 PE protocol. Metadata were deposited in the NCBI Sequence Read Archive under the accession no. SRP099176.
Data analysis.
To filter low-quality reads, we used the FASTXToolkit (http://hannonlab.cshl.edu/fastx_toolkit) to process the raw read data files. There were two steps of sequence quality processing. The command 'fastq_quality_filter -Q33 -q 30 -p 70'. '-q 30' indicated that the minimum quality score was 30. '-p 70' meant that bases must have a '-q' quality score of 70% or greater. Sequences were retained if both forward and reverse sequencing reads passed the first step.
An efficient sequence alignment tool, Bowtie2, was used to align the retained reads with human genome (Grch38.p2) (20) . Based on the results of sequence alignment, reads having only one chromosome location were retained for further analysis. The Genome Analysis Tool kit, is a widely used discovery tool to identify genetic variants based on the results of sequence alignment (21) .
Several databases and tools were used to annotate identified genetic variants. dbSNP (b144) is an archive of genetic variation within different species that provides information about each genetic variant (22) . ClinVar is a database of clinically significant genetic variants (23) . COSMIC (v73) collects somatic mutation information for human cancers (24) . The TCGA project collects genomics, methylomic and transcriptomic data across cancer types (25) . Integrated mutation prediction software (PolyPhen-2 and SIFT) were used for analyses of the identified variants (26, 27) . DrGaP was used to identify driver genes and driver signaling pathways (28) .
Confirmation by Sanger sequencing. Potential mutations identified by whole-exome sequencing were confirmed by PCR and Sanger sequencing. Specific PCR primers were designed using Primer3 software (primers can be provided on request). The products were sequenced directly with the ABI PRISM terminator cycle sequencing kit v3.1 on an ABI 3130 DNA sequencer (Applied Biosystems, Carlsbad, CA, USA).
Results
Whole-exome sequence analysis and coverage. Using massive parallel sequencing on a HiSeq platform, we generated ~45 billion bases of effective sequence data with an average read length of 200 bases. After mapping to the human reference genome (Grch38.p2) using the Bowtie 2 alignment tool, we obtained an average depth of coverage for the target regions of 20x for each sample (Table I ). The false positive and false negative rates were estimated to be 2.75% (12/437) and 19.69% (76/386), respectively, after confirmed by target sequencing of cancer-related genes (29) . were also detected in paired non-cancerous tissues (Fig. 1) .
Mutational landscape in the non-canonical cancer-related genes. The 1,271 non-synonymous mutations identified in this study, including 1,270 missense mutations and one nonsense mutation, were located at 1,144 genes. In total, 723 variants had previously been reported in the dbSNP, COSMIC or TCGA databases, while 548 variants in 516 genes had not (details can be provided on request). Table II . Overview of our approach to identifying driver and passenger genes in endometrial cancer. However, nearly all mutations had been reported in the 542 TCGA endometrial cancer samples. Only three mutations had never been reported (ARMCX4, CUTA and SAP30L). We selected these mutations for Sanger sequencing. CUTA p.T187R and SAP30L p.H77Y were also detected in paired non-cancerous tissues; ARMCX4 p.P2056H was the sole novel mutation that was detected only in cancer tissue (Fig. 2) . We also found 49 different mutations in the same codon of 49 non-canonical cancer-related genes compared with the TCGA database (details can be provided on request).
Remaining variants (n) --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
The 1,144 genes were divided into five groups according to mutation frequency. Fifteen non-canonical cancer-related genes had high frequencies of mutation (35.71-50%; 5-7/14) and four variants in three genes (IGSF10, FBXL13 and PRUNE2) were novel. We selected these new genetic variants for Sanger sequencing. We detected IGSF10 p.R455W, FBXL13 p.G313A and PRUNE2 p.S2439I in paired non-cancerous tissues, while IGSF10 p.K188Q was detected only in cancer tissue (Fig. 2) .
Six genes were mutated in 4 (28.57%) of the 14 patients. One gene (VPS13C) had a new genetic variant. Sanger sequencing confirmed that VPS13C p.V2017M was a novel mutation detected only in cancer tissue (Fig. 2) .
Twenty-two genes were mutated in 3 (21.43%) of the 14 patients, and there were 12 new genetic variants in 8 genes. We carried out Sanger sequencing on the new variants, and found that ARAP2 p.Y1491C, DNAH14 p.D4225V, TLN1 p.D1325E, TREH p.M196T and ZSCAN29 p.G304V were also present in paired non-cancerous tissues. Sanger sequencing also confirmed that DCT p.Y548S, DNAH14 p.G1566C, TLN1 p.A555V, ZNF605 p.P283Q, p.E652A and ZSCAN29 p.P71S were novel mutations present only in cancer tissue (Fig. 2) . One variant (TRANK1 p.W2445L) had an incorrect base call.
One hundred and nine genes were mutated in 2 (14.29%) of the 14 patients, and there were 73 new genetic variants in 54 genes. We ordered the 73 new variants according to sequencing depth. Next, we selected 10 variants for Sanger sequencing. Five variants had high depth (163x, 108x, 104x, 99x and 92x). Several novel mutations were detected only in cancer tissue, including MOCOS p.I320T, CMYA5 p.P2149H and PCDH17 p.P976H (Fig. 2) . MAGEE2 p.F249L and CRYBG3 p.Q632E were also detected in paired non-cancerous tissues. Five variants had low depth (all 20x). Novel mutations present only in cancer tissue including UGT1A8 p.Y290C and CYFIP2 p.C959Y (Fig. 2) , while APOL4 p.A316V and TRIM26 p.Q197H were also detected in paired non-cancerous tissues. One variant (MYO3B p.G230W) had an incorrect base call.
Among low-frequency mutations (7.14%; 1/14) in 992 noncanonical cancer-related genes, there were 458 new genetic variants in 450 genes. We ordered these 458 variants according to sequencing depth. Next, we selected 10 variants for Sanger sequencing. Five variants had high depth (286x, 244x, 223x, 197x and 187x). Several novel mutations were detected only in cancer tissue, including MACF1 p.Q181H, NUDT5 p.G135S, JAKMIP1 p.R352M and PCDHGB4 p.L154I (Fig. 2) . MYH10 p.L1048X was also detected in paired non-cancerous tissues. Five variants had low depth (all 20x). Novel mutations detected only in cancer tissue included FAM178A p.T86I, SNX6 p.L38R, IMP4 p.T163M and PCMTD1 p.A41D (Fig. 2) . TNFAIP8L3 p.A38T was also detected in the paired non-cancerous tissues.
ACMG gene. Of the 14 endometrial cancer samples, 28.57% (4/14) harbored ACMG mutations, including RYR2, MSH6 and TSC1, but did not have mutations in the remaining 53 genes. Mutations in the RYR2 gene were detected in 14.29% (2/14) of endometrial cancer specimens, with mutations at p.G1209R (rs770286824) and p.F4960L (a novel mutation) identified in our endometrial cancer samples. Both the MSH6 mutation at p.Q572H (rs745772518) and the TSC1 mutation (Fig. 3) . Moreover, we identified several cellular pathways that were altered in endometrial cancer tissues and we found that each sample had at least two pathways involved in the carcinogenesis of endometrial cancer (Fig. 4) .
Discussion
The present study described somatic mutation in the whole endometrial cancer exome. We identified several cancer driver and passengers genes from canonical and non-canonical cancer-related genes. Two canonical cancer-related genes (TSC1 and BIRC2) were found in the Oncomine Cancer Research Panel, which was used in the National Cancer Institute Match Trial (30) . TSC1 is a tumor suppressor gene that encodes a growth inhibitory protein (hamartin) thought to play a role in the stabilization of tuberin. TSC1 is a gene involved in the mTOR pathway. Mutations in TSC1, TSC2 and MTOR have been associated with response to rapalogs in patients with metastatic renal cell carcinoma (31) . We identified a novel mutation, p.D1054G, in one endometrial cancer patient.
BIRC2 is an oncogene that encodes c-IAP1, which is a member of the apoptosis inhibitor family. Members of this family inhibit apoptosis by binding to TRAF1 and TRAF2 and likely interfering with activation of ICE-like proteases. Previously, Choschzick et al (32) reported BIRC2 amplification in uterine cervix cancer. In the present study, we identified a novel mutation, p.P152S, in a patient with endometrial cancer.
The genetic alterations we found involved the mTOR, Wnt, MAPK, VEGF and ErbB pathways, as well as aberrant DNA repair, cell cycle control and apoptosis pathways. These pathways have previously been shown to be involved in the multistep development of endometrial cancer, and clinical trials of drugs for endometrial cancer that target these pathways have been carried out (33) . We also found genetic alterations in the steroid hormone biosynthesis pathway (hsa00140), including AKR1C3, CYP3A4, CYP3A43, HSD11B1, SULT1E1 and UGT1A8.
NGS technology allows for the detection of mutations and copy number variants. Although the hybrid capture method was used, we failed to assess copy number alterations because we sequenced only tumor samples. Sequencing coverage is uneven across the genome owing to variability introduced by the hybridization-capture step, and the development of a robust algorithm is challenging (34) . On the other hand, multiplex PCR-based method fail to detection copy number changes and/or gene fusions (13) . In summary, we performed WES of endometrial cancer samples and identified several potential cancer driver and passenger cancer genes (MAPT, IL24, MCM6, TSC1, BIRC2,  CIITA, DST, CASP8, NOTCH2, ARMCX4, IGSF10, VPS13C,  DCT, DNAH14, TLN1, ZNF605, ZSCAN29, MOCOS, CMYA5,  PCDH17, UGT1A8, CYFIP2, MACF1, NUDT5, JAKMIP1,  PCDHGB4 , FAM178A, SNX6, IMP4 and PCMTD1). The major limitation of this study was the small sample size.
